| abstract |
Compounds (many of which are new) that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF α or a condition involving a membrane-shedding event that is mediated by a metalloproteinase, are of formula (I): (B)2N-X-(CH2)m-W-(CR1R2)n-COY, wherein n= 0 or 1; m =0 or 1; X is S(O)1-2; Y is OH or NHOH; W is aryl or heteroaryl; and the other groups are as defined herein. |